Celesq® Presenters

Email For More Information

Sarah A. K.  Blitz, Esq.

Sarah Blitz is an associate in the Business Trial Practice Group in the firm's Los Angeles office. She is the leader of the firm’s Cannabis industry team and a member of the firm’s Food and Beverage industry and Product Liability teams.
Sarah specializes in commercial and business litigation. Her practice entails matters in state and federal court, including business torts, products liability, professional liability, breach of contract, breach of fiduciary duties and allegations of unfair business practice and fraud.


Sarah also advises cannabis companies and ancillary businesses on regulatory compliance. She also counsels consumer products manufacturers and distributors on products liability and regulatory compliance issues. Sarah also provides regulatory and product liability advice during acquisitions of consumer product and materials companies.
Sarah is experienced in all aspects of California and federal civil procedure, including motion practice, arguing motions in court, taking and defending depositions, trial and alternative dispute resolution proceedings. She also has significant appellate and writ experience before the California Court of Appeal.


Outside the firm, Sarah is involved with the Alliance of Moms. She formerly served on the Advisory Council for City Scholars Foundation. Sarah is also active with the Anti-Defamation League and a participant in the Glass Leadership Institute.

 

Programs by Sarah A. K.  Blitz, Esq..

Hemp-CBD infused products have taken the consumer market by storm, but their legality is not a foregone conclusion after the 2018 Farm Bill and operating in the Hemp-CBD space presents a variety of risks. This webinar will cover the 2018 Farm Bill, F...

Program Number
29147
Program Date
2019-09-25
Category
Cannabis LawConstitutional LawFederal CourtsHealth Care LawRegulatory and Administrative Law
State
CaliforniaGeorgiaNew JerseyNew YorkTexas Self Study

In September, the US Food and Drug Administration (FDA) published six guidance documents clarifying its scope of authority and enforcement discretion policies in light of the 21st Century Cures Act. The long-awaited draft guidance on Clinical Decisio...

Program Number
29214
Program Date
2019-12-16
Category
Administrative Law & RegulationsBankruptcy Law & Creditor RightsConstitutional LawFederal CourtsHealth Care LawPharmaceutical LawRegulatory and Administrative Law
State
CaliforniaGeorgiaNew JerseyNew YorkTexas Self Study